AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

Research

FDA approves first drug for reducing the risk of sexually acquired HIV infection

blog.aids.gov

Today (July 16, 2012), the U.S. Food and Drug Administration approved Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners. Truvada, taken daily, is to be used for…

Increasing HIV Testing, Including Rapid Testing, in Substance Abuse Treatment Programs

Dr. Valdiserri

Although the U.S. has made progress in reducing the number of new HIV infections among injection drug users and their sexual partners, CDC estimates that injection drug users represented 9% of new HIV infections in 2009 and 17% of those living with HIV in 2008.  Since the U.S. HIV/AIDS epidemic began, more than 175,000 injection…

Turning the Tide Together: Looking To the XIX International AIDS Conference in Washington, D.C.

Anthony Fauci

Next month, the International AIDS Conference returns to Washington, D.C., where it was last held in 1987. One of us (ASF) had the privilege of speaking at the 1987 conference, and will do so again this year. At the Washington conference 25 years ago, the mood was somber. The HIV/AIDS pandemic was expanding rapidly. Although…

FDA Advisory Committees to Examine a Number of HIV Issues in May

FDA

The U.S. Food and Drug Administration (FDA) has three important advisory committee meetings scheduled in May that may impact HIV prevention, detection, and treatment. On May 10, 2012, FDA’s Antiviral Advisory Committee will discuss expanding the indication of Truvada (emtricitabine/tenofovir disoproxil fumarate) tablet, made by Gilead Sciences, Inc., to include use for Pre-Exposure Prophylaxis (PrEP),…

Updated HHS Adult and Adolescent Antiretroviral Treatment Guidelines Now Available

AIDS Info Guidelines

The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents released updated Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents last week. Revisions to the October 14, 2011, version of the guidelines include both new sections and key updates to existing sections, including: New section on HIV and the older patient…

Conversation from CROI: Dr. Jonathan Mermin on PrEP and an AIDS-free Generation

Mermin YouTube still

At the recent 19th Conference on Retroviruses and Opportunistic Infections (CROI), Dr. Ron Valdiserri, Deputy Assistant Secretary of Health for Infectious Diseases, spoke with Dr. Jonathan Mermin, Director of CDC’s Division of HIV/AIDS Prevention. They discussed some of the significant findings from the conference including advances related to pre-exposure prophylaxis (PrEP) and the growing discussions…

New Frontiers in HIV Testing

Ronald Validserri

It is understandable why advances in the development of anti-HIV drugs have so dominated media stories about the AIDS epidemic in recent years. The advent of highly active antiretroviral therapy has had such a tremendous impact on HIV morbidity and mortality that early commentators of the phenomenon often referred to “the Lazarus effect” when describing…

The Impact of Missed Health Care Visits on HIV Outcomes and Mortality

Michael Holberg and Ron Valdiserri

At the 19th Conference on Retroviruses and Opportunistic Infections (CROI) [external disclaimer] this week, Dr. Ron Valdiserri, Deputy Assistant Secretary of Health for Infectious Diseases, spoke with Dr. Michael Horberg, Director of HIV/AIDS for Kaiser Permanente and a member of the Presidential Advisory Council on HIV/AIDS (PACHA). They discussed the paper Dr. Horberg is presenting…